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Abstract: Identifying specific somatic mutations that drive tumor 
growth has transformed the treatment of lung cancer. For example, 
cancers with sensitizing epidermal growth factor receptor  mutations 
and echinoderm microtubule-associated protein-like 4-anaplastic lym-
phoma kinase translocations can have remarkable responses to epider-
mal growth factor receptor  and ALK inhibitors respectively, leading 
to significant clinical benefit. However, effective molecularly targeted 
therapies have disproportionately impacted adenocarcinomas compared 
to squamous cell carcinomas, and never or light smokers compared to 
heavy smokers. Further progress in non–small-cell lung cancer will 
require the identification and effective targeting of molecular alterations 
in all subtypes of lung cancer. Here, we review the current knowledge 
about the molecular alterations found in squamous cell carcinoma of 
the lung. First, we will discuss the ongoing efforts to comprehensively 
assess the squamous cell carcinoma genome. We will then discuss the 
evidence supporting the role of specific genes in driving squamous cell 
carcinomas. By describing the landscape of somatic targets in squamous 
cell lung cancer, we hope to crystallize the current understanding of 
potential targets, spur development of therapies that can have clinical 
impact, and underscore the importance of new discoveries in this field.
Key Words: Squamous cell carcinoma of the lung, Molecular tar-
gets, Somatic mutations.
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SQUAMOUS CELL CANCER IS A DISTINCT 
THERAPEUTIC SUBSET
Lung cancer is the leading cause of cancer-related deaths 
in the United States, with more than 220,000 new cases and 
more than 157,000 deaths annually.1 Approximately 85% of the 
newly diagnosed lung cancers are non–small-cell lung cancer 
(NSCLC), and of these, approximately 30% are squamous cell 
carcinoma. Historically, approaches to the treatment of NSCLC 
were uniform, and histologic subtypes within NSCLC did 
not significantly affect treatment decisions.2 However, recent 
advances in NSCLC drug development have introduced his-
tology as an important factor that can alter treatment options. 
For example, bevacizumab is contraindicated in patients with 
squamous cell lung cancer, because of an increased risk of fatal 
hemoptysis.3,4 Pemetrexed is approved for the treatment of non-
squamous NSCLC only, as multiple studies have shown greater 
efficacy in nonsquamous as compared to squamous cancers.5–8
Although the selection of drugs by histology is one 
refinement on the previous approach, ultimately the field is 
evolving toward classifying lung cancers according to the spe-
cific somatic mutations that drive tumor growth. For example, 
cancers with sensitizing epidermal growth factor receptor 
(EGFR) mutations and echinoderm microtubule-associated 
protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) 
translocations can have remarkable responses to EGFR and 
ALK inhibitors respectively, leading to significant clinical 
benefit.9–14 However, effective molecularly targeted therapies 
have disproportionately impacted adenocarcinomas compared 
to squamous cell carcinomas, and never or light smokers 
compared to heavy smokers. Further progress in NSCLC will 
require the identification and effective targeting of molecular 
alterations in all subtypes of lung cancer.
Here we review the current knowledge about the molec-
ular alterations found in squamous cell carcinoma of the lung. 
First, we will discuss the ongoing efforts to comprehensively 
assess the squamous cell carcinoma genome. We will then dis-
cuss the evidence supporting the role of specific genes in driv-
ing squamous cell carcinomas. By describing the landscape 
of somatic targets in squamous cell lung cancer, we hope to 
crystallize the current understanding of potential targets, spur 
development of therapies that can have clinical impact, and 
underscore the importance of new discoveries in this field.
COMPREHENSIVE GENOMIC STUDIES 
IDENTIFYING SOMATIC GENE ALTERATIONS  
IN LUNG SQUAMOUS CELL CANCER
Mutations
Next-generation sequencing technologies are allowing 
better characterization of cancer genomes.15 Multiple investiga-
tors have reported genomic alterations in cancers, using high-
throughput sequencing technologies.16–20 In lung cancer, efforts 
assessing somatic mutation and copy number alteration (CNA) 
profiles were initially confined to adenocarcinoma.17,18 More 
recently, studies have included squamous cell lung cancers as 
well. Kan et al.19 identified 2500 somatic mutation events in 967 
of the 1507 candidate genes studied across a broad range of 
tumor types. In general, lung cancers had a high rate of pro-
tein-altering mutations, with adenocarcinomas and squamous 
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cell carcinomas of the lung having rates of 3.5 and 3.9 per Mb 
respectively, compared to the rate of 1.8 per Mb across all tumor 
types. This attests to the genomic complexity of lung cancers 
and the comparative difficulty of effectively treating these 
tumors. As would be expected, mutated cancer genes identified 
in squamous cell lung carcinoma are distinct from the cancer 
genes found in lung adenocarcinoma. Some of the more com-
monly mutated genes observed in squamous cell lung cancers 
included TP53, GRM8, BAI3, ERBB4, RUNX1T1, KEAP1, 
FBXW7, KRAS, among others.19 The Cancer Genome Atlas, 
a project funded by National Institutes of Health and National 
Human Genome Research Institute to define the somatic 
genomic changes in more than 20 different types of cancer, is 
actively performing analyses on lung squamous cancers, and 
results from this effort are expected later this year.
As systemic mutation screens are performed, it is 
important to separate “driver” mutations, which confer growth 
advantage and are causally related to cancer development, 
versus “passenger” mutations, which are biologically neutral 
and do not confer growth advantage.21,22 Although it is clear 
that the somatic mutation rate in squamous cell lung cancer 
is high, indeed higher than what is seen in many other solid 
cancers, it is possible that many of the observed mutations 
may be “passenger” mutations. Identifying strategies to effec-
tively match drug therapies to tumors relies on targeting the 
key “driver” mutations, so this distinction will be critical.22
one potential method to help identify driver mutations 
may be to interrogate signaling pathways to see which genes are 
actually activated in these cancers (Fig. 1). Rikova et al.23 inves-
tigated phosphotyrosine signaling in lung cancer cell lines and 
tumors to identify aberrant tyrosine kinase signaling in lung can-
cer. Squamous cell cancers that were tested in this way showed 
activation in multiple kinase pathways, including DDR1, DDR2, 
VEGFR1, VEGFR2, PDGFRa, MET, EPHA2, and EPHB3.23 As 
discussed later, these genes are among the key candidate driver 
mutations thought to be altered in squamous cell lung cancer.
Copy Number Alterations
In addition to mutations, comparative genomic hybrid-
ization studies and loss of heterozygosity studies have demon-
strated the frequency with which CNAs can occur in cancer. 
CNAs can help identify areas of amplification or loss of genetic 
material, which may signal oncogenic or tumor suppressor 
candidate genes. Recurring CNAs in lung cancer have been 
identified and most frequently involve gains in 1q31, 3q25–27, 
5p13–14, 8q23–24, and losses in 3p21, 8p22, 9p21–22, 13q22, 
17p12–13, among others.24–31 Although many of these areas of 
CNA are common to both squamous carcinoma and adenocar-
cinoma of the lung, a few regions seem to be more common in 
squamous histology, including gain in 3q2624,27,32–34 and gain 
in 8p12.35 Candidate genes in these areas include PI3KCA, 
SoX2, p63, SSCRo/DCUND1, TERC, in 3q26,29,30,33,36–39 and 
BRF2, FGFR1, and WHSC1L1 for 8p12.29,35,40
CANDIDATE GENES IN SQUAMOUS  
CELL LUNG CANCER
In this part of the review, we will discuss specific candi-
date genes and the literature supporting their roles as oncogenic 
drivers in squamous cell lung cancer. A literature search was 
conducted for articles on PubMed published between 1990 
and 2011, using the search terms “squamous cell lung cancer,” 
which were combined with the terms “somatic mutations,” 
“amplification,” “genetics,” and “loss of heterozygosity.” 
Articles not available in English were excluded. Germline 
genetic changes and microRNA alterations were excluded 
as they are beyond the scope of this review. Further specific 
searches were performed in PubMed for the individual genes 
that were reported in genomic studies that included squamous 
lung cancer. In this review we focused primarily on activating 
mutations and overexpression or amplification as the genomic 
change of interest rather than loss of expression, because tar-
geted therapies have to date been most successful against these 
classes of genetic changes. However, it is possible though 
not yet proven that some tumor suppressor changes, such as 
PTEN loss, may be successfully targeted, for example with 
phosphatidylinositol 3-kinase (PI3K) inhibitors; therefore, we 
have included some discussion of this topic. overall, the pri-
mary focus of this review is on two classes of gene alterations: 
(1) overexpression or amplification and (2) point mutation. 
Notably, some candidate genes demonstrate both mechanisms 
of activation (Table 1). Both types of genetic activation can 
potentially be effectively targeted with therapeutic agents. For 
example, trastuzumab is effective in HER2-amplified breast 
cancers and gefitinib or erlotinib is effective in EGFR-mutant 
lung cancers. Which of the alterations reported in squamous 
cell lung cancer are truly “driver” mutations, and could be 
effectively targeted, remains to be seen and is an area of 
active inquiry. Table 2 shows some of the drugs currently in 
clinical trials, which target specific oncogenic changes and 
may be relevant in squamous cell lung cancer.
SOX2
Amplification of 3q26 is one of the most frequently 
reported alterations in squamous cell lung cancer. SoX2 has 
been implicated as a candidate gene in this area, with high-
level amplification of SoX2 reported in approximately 20% 
of lung squamous cell carcinomas.39,41 SoX2 is a transcrip-
tion factor and a critical regulator of normal stem cell func-
tion in embryonic and neural stem cells; it is thought to play 
a key role in the development of lung epithelium. Bass et al. 
showed that RNA interference knockdown of SoX2 reduced 
cellular proliferation, and that suppression of SoX2 had a 
greater effect on growth compared to other candidate genes at 
the 3q26 locus including PIK3CA and TP63. However, SoX2 
alone was not transforming, which is generally a requirement 
for a “driver” event. Similarly, Hussenet et al.41 showed that 
overexpression of SoX2 in cell culture leads to migration 
and anchorage independent growth, and knockdown of SoX2 
impairs growth. However, difference in cell-invasion capacity 
was not seen, and the rate of tumor growth was slow, sug-
gesting that other hits are required to be fully transforming.41 
overexpression of SoX2 in mouse models leads to extensive 
hyperplasia and carcinoma in those with the highest levels of 
SoX2.42 The bulk of evidence suggests that SoX2 amplifica-
tion may represent a “priming event” that requires additional 
downstream events43 to be fully transforming. There are no 
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SoX2 inhibitors in clinical trials at the moment (see Table 2 
for specific targeted agents in clinical trials).
PIK3CA
PIK3CA is another candidate gene that is found in the 
3q26 amplified area. PIK3CA encodes the gene for the cata-
lytic subunit (p110) of PI3K. The PI3K-AKT pathway plays a 
central role in the survival and proliferation of many cancers.44 
Both copy-number gains and mutations in PIK3CA have been 
identified in lung cancer. PIK3CA copy-number gains occur 
in approximately 20% of lung cancers, with higher frequency 
in squamous cell carcinomas.45–47 Amplification presumably 
leads to activation of PI3K pathway cell signaling, but the 
details of this mechanism are not yet clear.
Somatic mutations in PIK3CA have also been described 
and promote activation of the PI3K-signaling pathway.48 
Mutations in PIK3CA are clustered in two hotspot regions in 
exons 9 and 20 encoding the helical and kinase domains of 
the protein, respectively. These mutations lead to increased 
lipid kinase activity and constitutive PI3K-AKT signaling.48,49 
The mechanism of action is different based on mutation type; 
for example, the helical-domain mutants E545K and E542K 
interfere with the inhibitory interaction between the regula-
tory subunit p85 and the catalytic unit p110, whereas the 
kinase domain mutant H1047R is located near the activation 
loop, and leads to constitutive signaling through the kinase.49 
PIK3CA mutations have been reported in 1% to 5% of the 
NSCLC cell lines and tumors.45,50 Kawano et al.50 found 
PIK3CA mutations in 6.5 % of lung squamous cell carcino-
mas, and less often in lung adenocarcinomas (1.5%). There 
are multiple PI3K inhibitors in development, with specificity 
ranging from dual PI3K/MToR inhibition to pan-PI3K and 
isoform-selective PI3K inhibitors (see Table 2). Preclinical data 
suggest that cancers harboring activating mutations in PIK3CA 
are among the most sensitive to single-agent PI3K-pathway 
inhibitors.49 As clinical trials with PI3K-pathway inhibitors 
accrue squamous cell carcinomas with PIK3CA mutations, 
we need to examine if these cancers are truly addicted to PI3K 
signaling. Combinations of PI3K inhibitors with inhibitors of 
other cancer-related pathways are also being actively tested as 
investigators try to suppress multiple therapeutic pathways.
FGFR1
Amplification at 8p12 was observed in multiple studies 
of squamous cell lung cancer,39,51 and FGFR1 has been identi-
fied as a potential candidate gene in this region. FGFR1 is a 
member of the FGFR family of receptor tyrosine kinases; acti-
vation leads to downstream signaling via PI3K/AKT, RAS/
TABLE 1. Key Candidate Genes in Squamous Cell Lung Cancer
Gene
Amplification Mutation
Level of 
Evidence Presence in Other Cancers RefSquamous Adeno Squamous Adeno
FGFR1 20% 1% 1,2 Breast, prostate, myeloproliferative 
d/o—bladder rather than prostate?
51
SoX 20% n.r. 1,2 Esophageal 39,41
PIK3CA 20% 5% 6% 1.5% 1,2 Breast, CRC, GBM, HCC, ovarian, 
gastric, H&N, thyroid, esophageal, 
cervical
44,45,47
MDM2 10% 5% 1,2 Sarcoma, esophageal, brain, breast, 
H&N, testicular
84,85
PDGFRA 8–10% 3–7% 1 2 GBM 76
MET 6% <5% 1,2,3 Gastric, esophageal 74
P53 65% 40% 1,2 Most commonly mutated gene 
across all cancers
78–80
NRF2 10–15% 1–2% 1,2 H&N, esophageal, squamous cell 
of skin
114,115
PTEN 10.2% 1.7% 1,2 GBM, prostate, breast, gastric, 
melanoma, endometrial, bladder
111–113
EPHA2 7% 0 1,2 Breast, prostate, ovary, esophagus, 
pancreas
69
LKB1 5% 13% 1,2 Cervical 108,109
AKT 5% 0 1,2 Breast, CRC, ovarian 86,87
EGFR vIII 5% 0 1,2 GBM 94–96
DDR2 3–4% n.r. 1,2 n.r. 102
PTEN loss IHC expression 70–75%
hypermethylation 30–35%
LoH 18–22%
not significantly different by histology
1,2 GBM, prostate, breast, gastric, 
melanoma, thyroid, bladder
111,112
Level of evidence: 
Genomic change reported in primary tumors and cell lines: 1
Functional studies performed showing proliferative effects: 2
Clinical trials demonstrating ability to target genetic alteration and inhibit tumor growth in patients: 3
n.r., not reported; CRC, colorectal cancer; GBM, glioblastoma; HCC, hepatocellular carcinoma; H&N, head and neck cancer.
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MAPK pathways that are central to growth, survival migra-
tion, and angiogenesis in many cancers.52 Dysregulation of the 
FGFR1-4 signaling has been described in multiple cancers, 
with overexpression seen in breast, prostate, myeloma, and 
point mutations observed in sarcoma, bladder, and endome-
trial cancers, among others.53,54 In lung cancer, FGFR1 ampli-
fication was enriched in squamous cell cancers in comparison 
to adenocarcinomas, with approximately 20% of squamous 
cells having FGFR1 amplification.51 Inhibition of FGFR1 
both in cell lines and in mouse models with FGFR1-amplified 
engrafted tumors showed growth inhibition and induced apop-
tosis.51 FGFR1 mutations were rare. Multiple FGFR inhibitors 
are in development; many of these are multitargeted tyrosine 
kinase inhibitors (TKIs), which have activity against other 
targets in addition to FGFR1. Some current trials are specifi-
cally targeting lung cancers harboring FGFR1 amplification 
(ClinicalTrials.gov).
IGF1R
The insulin-like growth factor pathway is important in 
embryonic development, growth, and metabolism, and dys-
regulation of the insulin-like growth factor pathway has been 
described in multiple tumor types.55 IGF1R activation trig-
gers downstream pathways, including the RAS/RAF/MAPK 
pathway and the PI3K pathway, leading to cell proliferation 
and inhibition of programmed cell death. In lung cancer, over-
expression of IGF1R (located on 15q26) is more commonly 
TABLE 2. Selected Drugs Targeting Potential Oncogenic 
Drivers
TARGET Drug Company Phase
PI3K GDC0032 Genentech I
ZSTK474 Zenyaku Kogyo I
GDC0941 Genentech I
BYL719a Novartis I
AMG319 Amgen I
INK1117a Intellikine I
BKM120 Novartis I, II
CAL101 Gilead I,II
PX-866 oncothyreon I, II
Xl147 SAR245408 Sanofi-Aventis I, II
PI3K/MToR GSK2126458 GSK I
PF-04691502 Pfizer I
DS-7423 Daichii-Sanyko I
GDC0980 Genentech I
Bay806946 Bayer I
PKI587 Pfizer I
SF1126 Semafore I
BEZ235 Novartis I,II
Xl765 SAR245409 Sanofi-Aventis I, II
FGFR E-3810 EoS I
BGJ398 Novartis I
Azd4547 AZ I, II
Brivanib Bristol Myers Squibb I, II
EPHA2 MEDI547 medimmune I, II
Dasatinib Bristol Myers Squibb II
MET INC280 Novartis I
EMD 1214063 EMD Serono I
Amg208 Amgen I
Amg337 Amgen I
XL184 Exelixis I, II
AV299 Aveo I, II
GSK1363089 GSK I, II
Tivantinib Daiichi-Sankyo I, II, III
MetMab Genentech II, III
PDGFR Pazopanib Glaxo Smith Kline I, II
IMC-3G3 ImClone II
CP-868,596 Arog Pharmaceuticals II
AG-013736 Pfizer II
MEDI575 AZ I, II, III
IGF1R BIIB022 Biogen I
AXL1717 Axelar AB I
AMG479 Amgen II
R1507 Roche I, II
IMC-1A2 ImClone I,II
MK0646 Merck I, II
osi906 oSI I, II
AVE1642 Sanofi-Aventis II
Figutumumab Pfizer Phase III, 
terminated
AKT GSK690693 GSK I
GSK2141795 GSK I
Mk2206 Merck I, II
Abstracted from clinicaltrials.gov.
aAlpha selective.
FGFR
PDGFR
MET
RAS
P13K
RAF
MEK
ERK
AKT
TP53
PTEN
MDM2
FIGURE 1. Interrelationship of signaling pathways involved 
in genomic alterations seen in squamous cell lung cancer.
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seen in squamous cell as compared to other histologies.56–58 
However, genetic activation of this pathway has not been 
reported. A great deal of clinical interest was spurred by the 
early results from a randomized Phase II study of chemother-
apy with or without figitumumab, an antibody against IGF1R, 
which showed promising activity in Phase-II studies, especially 
among patients with squamous cell lung cancer.59 Biomarker 
analyses in a subset of patients suggested benefit among those 
with higher levels of IGF160 or higher tumoral IGF1R levels 
in squamous cell cancers61; although, numbers were small in 
these analyses. oddly, higher IGF1 levels were observed in 
adenocarcinoma whereas those patients with squamous cell 
histology were reported to have more benefit in the study 
as a whole, throwing into question whether these biomark-
ers were truly predictive. Two Phase-III studies with figitu-
mumab in combination with either chemotherapy or erlotinib 
were recently closed because of futility and increased toxicity, 
and further development of this class of agents is in question. 
Small molecule TKIs of IGFR1 are also being studied, and a 
challenge with this class of drugs is hitting the IGFR1 target 
selectively, given the crossreactivity with insulin receptor.
EphA2
The Eph receptor family is a group of receptor tyrosine 
kinases that are divided into EphA and EphB based on struc-
tural homology and ligand affinity. Eph receptors are impor-
tant in embryonic development such as cell migration, vascular 
development, and tissue-border formation.62 overexpression 
of EphA2 (located on chromosome 1p36) is seen in multiple 
cancers, including NSCLC,63,64 and is thought to promote cell 
motility, invasion, metastasis, and angiogenesis.65–68 EphA2 
expression has been correlated with smoking and worse sur-
vival, and has been reported to be higher in metastatic lesions 
as compared to primary sites.63,64 In addition to overexpres-
sion, mutations in EphA2 have been described; although 
overall rare, they are found more commonly in squamous 
cell as compared to nonsquamous lung tumors. A mutation 
in EphA2 (G391R) was identified in two of 28  squamous cell 
lung cancers (7%), but not in any adenocarcinomas or large 
-cell lung carcinomas.69 overexpression of both the wildtype 
and mutated EphA2 increases cellular invasiveness, with the 
effect being more pronounced with the mutated receptor.69 
overexpression of EphA2 leads to increased phosphoryla-
tion of SRC, Cortactin, and p130Cas. of note, the activity of 
p130Cas is particularly important in G391R mutated cells. 
These findings lead to the emergence of EphA2 as a poten-
tial target for drug development. Dasatinib, a multitargeted 
TKI, has activity against Eph family receptors in addition to 
BCR-ABL, KIT, and SRC tyrosine kinases, and more specific 
EphA2 inhibitors are also under development.
MET
MET (located on 7q31) encodes a receptor tyrosine 
kinase for hepatocyte growth factor, and overexpression of 
MET has been linked with abnormal cell proliferation and 
invasion.70 Cells with MET amplification demonstrate high 
sensitivity to MET inhibitors,71 and a lung cancer with MET 
amplification demonstrated high sensitivity to the ALK/MET 
inhibitor, crizotinib,72 suggesting cancers with true amplifi-
cation may be sensitive to MET inhibitors. MET amplifica-
tion has also been identified as a mechanism of resistance for 
EGFR TKI therapy.73 Both copy-number gain/high polysomy 
and true amplification of MET have been identified in NSCLC. 
Although copy-number gain/high polysomy seems to have no 
association with specific histology, true amplification may be 
more common in squamous cell compared to nonsquamous.74 
MET amplification was found in six of 97  squamous patients 
(6.2%) and was associated with worse prognosis.74 There are 
multiple MET inhibitors currently being tested in clinical trials. 
The best selection criteria for targeting MET (i.e., overexpres-
sion versus copy-number gain versus amplification) remains 
to be seen; for example, a recent study showed that MetMab, 
an antibody against MET, had a progression-free survival and 
overall-survival benefit for patients who received erlotinib 
with MetMab versus erlotinib alone, among patients who 
overexpressed MET (defined as  50% tumor with moderate/
strong MET expression).75 Approximately 30% of the patients 
on this study had squamous histology, and the numbers with 
squamous and MET overexpression are too small in this study 
to draw conclusions regarding histology. Median progression-
free survival was 2.9 months for those receiving MetMab with 
erlotinib versus 1.5 months for erlotinib alone among those 
with MET overexpression (p = 0.04), while median overall 
survival was 12.6 versus 3.8 months (p = 0.002). on the basis 
of these results a Phase-III study is planned. Multiple other 
MET inhibitors are in clinical development.
PDGFRA/ 4q12 Amplification
Amplification of 4q12 has been reported in 3% to 7% of 
lung adenocarcinomas and 8% to 10% of lung squamous cell 
carcinomas.76 PDGFRA and KIT map to the region of focal 
amplification. Abnormalities in PDGFR have been identified 
in multiple cancers including hematologic malignancies, GIST, 
medulloblastomas, and gliomas.77 PDGFRA amplification is 
seen in a lung squamous cell cancer cell line (NCI-H1703), 
and short hairpin RNA knockdown and small-molecule inhibi-
tion of PDGFRA inhibit cell survival and anchorage indepen-
dent growth, suggesting that in a subset of NSCLC PDGFRA 
may be an essential oncogene.76 Multiple PDGFRA inhibitors 
are in clinical development. Multitargeted kinases such as 
sunitinib, which target PDGFRA and multiple other targets 
have been tested in lung cancer previously, although not spe-
cifically by genotype or squamous histology; more selective 
inhibitors are also in development.
p53/MDM2
The p53 tumor suppressor gene (located on 17p13) 
functions mainly as a transcription factor, binding specific 
DNA sequences, and activating or repressing genes that regu-
late cell cycle arrest, apoptosis, and DNA repair.78 Inactivation 
of p53 is important for cancer cell survival across multiple 
tumor types, and is one of the most commonly found altera-
tions in cancer.
Mutations in p53 are a frequent event in lung can-
cer, seen in more than half of NSCLCs, and approximately 
65% of squamous cell carcinomas.79 Mutational hotspots are 
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concentrated in the sequence-specific DNA-binding domain, 
and approximately 75% of mutations are missense80 and lead to 
loss of function as a transcription factor. The mutational spec-
tra are affected by smoking,80,81 and show excess of G->T tran-
versions, which are linked to polycyclic aromatic hydrocarbon 
(PAH) adducts. Interestingly, there is a correlation between 
p53 mutational hotspots and hotspots of adduct formation by 
PAHs.82,83 Accumulation of nonfunctional mutant p53 leads to 
high concentrations of mutant p53 in tumor cells.
In addition to mutations in p53, inactivation of wild-
type p53 can be seen, which can also dysregulate the p53 path-
way and promote carcinogenesis. In a substantial number of 
tumors, wild-type p53 is inactivated by MDM2 overexpression 
or amplification; normally, MDM2 and p53 are tightly regu-
lated in a negative feedback loop where MDM2 ubiquinates 
p53 and marks it for degradation; overexpression of MDM2 
therefore leads to inactivation of p53.78 MDM2 amplification 
(located on 12q14) has been reported in 6% to 7% of NSCLC, 
in both adenocarcinoma and squamous cell carcinoma84,85 and 
tends to be an exclusive event of p53 mutation.84
Targeting the p53 axis has been difficult, as p53 is a 
transcription factor with complex protein–protein interac-
tions, without an easily accessible receptor–ligand interaction 
or enzymatic active site that would render it a more easily 
druggable target.78 Multiple approaches to targeting p53 have 
been attempted, including adenovirus-based gene therapy, and 
more recently small molecules designed to attempt to activate 
endogenous p53 in tumors retaining the wild-type gene. one 
potential strategy is the development of small molecules that 
to try to increase p53 activity by neutralizing MDM2, includ-
ing nutlins that bind and dissociate MDM2 from p53. Small 
molecules targeting mutant p53 are also in development but 
are an even greater challenge to develop, given the wide range 
of mutant proteins that are expressed.78
AKT
A somatic mutation in AKT (located on 14q32), E17K, 
constitutively activates the protein kinase.86 The AKT1 E17K 
mutation was found in two of 36 squamous cell lung cancers 
(5.5%), but not in lung adenocarcinoma (zero of 53).87 Both 
patients with the mutation were male smokers with squamous 
cell carcinoma. Examples of AKT inhibitors in clinical devel-
opment are shown in Table 3. It remains unknown whether 
cancers with these mutations will be sensitive to single-agent 
AKT inhibitors.
EGFR
The activating mutations in the EGFR (located on 7p12) 
tyrosine kinase domain that confer exquisite sensitivity to 
EGFR tyrosine kinase inhibition are found in adenocarcinoma 
and bronchioloalveolar histologies rather than squamous cell 
carcinoma. However, alterations involving EGFR are found in 
squamous cell lung cancer in the form of copy-number gains 
and variant-III mutations.
In squamous cell lung cancers, high EGFR gene copy-
number and protein overexpression are observed more fre-
quently than in adenocarcinoma (82% versus 44%).88–91 
Although EGFR overexpression has been associated with 
worse prognosis in some studies, it has not been associated 
with response to the EGFR TKIs used clinically. A retrospec-
tive analysis of FLEX, a large Phase-III study evaluating 
chemotherapy with or without the anti-EGFR antibody cetux-
imab, suggested that EGFR overexpression may be associated 
with better outcomes in the cetuximab arm,92 but these find-
ings have not been confirmed in other studies.93
The variant-III (vIII) in-frame deletion of exons 2 to 7 
in EGFR, which was initially described in glioblastoma,94,95 
causes a deletion in the extracellular domain that has an 
activating effect on the receptor, leading to a proliferative 
advantage in cells expressing these truncated receptors. The 
EGFR vIII mutation was found to be present in three of 56 
squamous cell lung cancers (5%), but in none of the 123 
lung adenocarcinomas.96 In mouse models, expression of the 
EGFRvIII mutation led to the development of NSCLC, and 
inhibition with an irreversible EGFR inhibitor caused tumor 
regression.95 EGFR-vIII mutations were found in eight of 252 
patients with lung cancer in one study; all were male smok-
ers, and seven had squamous cell carcinoma.97 It should be 
noted that BR.21 showed benefit of erlotinib in squamous cell 
cancers and adenocarcinomas. More specific molecular cor-
relative data regarding copy number or EGFR-vIII mutation in 
the squamous patients are not available; however, preclinical 
studies would suggest that reversible EGFR inhibitors such as 
erlotinib or gefitinib would not have significant activity against 
the vIII mutation specifically because the kinase domain of 
vIII would have the same affinitiy toward gefitinib/erlotinib as 
the wild-type EGFR, and thus we would not observe the same 
therapeutic window we observe with exon 19 and 21 mutant 
EGFR. However, it remains possible that cancers with vIII are 
“addicted” to EGFR signaling and could still be potentially 
sensitive to therapeutic inhibition of the EGFR-signaling 
pathway.
DDR2
DDR2 (located on 1q23) is a receptor tyrosine kinase that 
binds collagen and has been shown to promote cell migration, 
proliferation, and survival.98,99 Mutations in DDR2 have been 
reported in lung cancer, although with varying frequency.100,101 
Looking specifically at squamous cell lung cancers, DDR2 
kinase gene mutations were identified in 3.8% of squamous 
cell lung cancers and cell lines (nine out of 277 squamous cell 
tumors, 3.2%).102 Knockdown of DDR2 by RNA interference 
or by dasatinib in cell lines with DDR2 mutations led to inhibi-
tion of proliferation, and ectopic expression of mutated DDR2 
led to cellular transformation, although to varying degrees. 
Although preliminary, these results suggest that these muta-
tions may be oncogenic, and cancers with mutations in DDR2 
may be sensitive to drugs that inhibit its kinase activity.
LKB1
LKB1 (located on 19p13) is a serine–threonine kinase 
that regulates cell-cycle progression, apoptosis, and polarity.103 
LKB mutation rates seem to be higher in whites compared to 
Asian populations,104–107 and seem to be correlated with smok-
ing and kras mutations.107 Although inactivation of LKB1 
is more commonly associated with adenocarcinoma, it has 
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been seen in squamous cell cancers as well. Genomic altera-
tions in LKB1 was found in 34% adenocarcinomas and 19% 
squamous cell carcinomas in one study of NSCLCs, with most 
of these being single copy mutations or deletions.108 Mutations 
in LKB1 were detected in 11% of lung cancers tested, and 
more commonly in adenocarcinomas (13%) versus squamous 
(5%).109 The majority of mutations were deletions or inser-
tions, with some missense or nonsense mutations also being 
observed. Interestingly, the mutations were more common in 
a U.S. cohort compared to an Asian one; in the United States, 
LKB1 mutations were seen in 19% of adenocarcinomas and 
13% of squamous, whereas the Asian cohort had only an 8% 
mutation rate in adeno and 0% in squamous. In mouse models, 
LKB1 inactivation in combination with activating mutations 
in kras led to lung tumor growth with frequent metastasis; 
LKB1 inactivation led to both adenocarcinoma and squamous 
tumors in these mouse models.108 Signaling through activated 
SRC and focal adhesion kinase pathways may be important in 
increasing cell migration and invasiveness in LKB1-deficient 
lung cancers,110 and a combination of PI3K, MToR, MEK, 
and SRC inhibition may be a useful treatment strategy in these 
cancers.
PTEN
The tumor-suppressor gene PTEN (located on 10q23) 
encodes a lipid phosphatase that negatively regulates the 
PI3K/AKT pathway, and loss of PTEN leads to constitutive 
PI3K-AKT signaling. Somatic PTEN deletions and mutations 
and inactivation of PTEN by epigenetic mechanisms such 
as methylation or microRNA silencing are seen in multiple 
cancers.111 Reduction or loss of PTEN expression has been 
reported in up to 70% of NSCLC, both adenocarcinoma and 
squamous cell.112 In addition, PTEN mutations occuring in 
approximately 5% of lung cancers are significantly associated 
with squamous cell rather than adenocarcinoma histology 
(10.2% versus 1.7%).113 Cancers with PTEN loss may be more 
sensitive to inhibitors of the PI3K pathway, although definitive 
data are lacking. Clinical trials of PI3K inhibitors in cancers 
with PTEN loss are ongoing and should provide much needed 
insight into this question.
NRF2/KEAP1
Nuclear factor erythroid-2–related factor 2 (NRF2, 
located on 2q31) is a transcription factor that regulates the 
expression of cytoprotective genes that are normally induced 
in response to environmental and endogenous oxidative stress. 
Kelch-like ECH-associated protein 1 (KEAP1, located on 
19p13) negatively regulates NRF2 activity by targeting it for 
degradation. Somatic mutations in NRF2 have been reported in 
human cancers, especially among those with smoking history 
or squamous histology. These mutations block proper NRF2-
KEAP1 binding and inhibit KEAP1-mediated degradation of 
NRF2.114 NRF2 mutations have been found in 8% to 11% of 
lung cancers in predominantly squamous histology, and have 
also been reported in squamous cell cancers of esophageal, 
larynx, and skin primary sites.114,115 In contrast, KEAP1 muta-
tions and loss of heterozygosity of KEAP1 have been identi-
fied in lung cancer and lead to NRF2 activation; however, these 
have been seen predominantly in adenocarcinoma, although 
the numbers analyzed to date have been small.116 In addition 
to mutations, aberrant NRF2 and KEAP2 expression is found 
in lung cancer at rates higher than mutation rates, suggesting 
that other mechanisms for NRF2/KEAP1 pathway dysregula-
tion are involved as well: NRF2 expression was found in 26% 
of NSCLC, more commonly in squamous versus adenocarci-
noma (38% versus 18%, p < 0.0001), whereas low or absent 
KEAP1 was significantly more common in adenocarcinoma 
than squamous (62% versus 46%, p = 0.0057).117 There are 
currently no specific drugs targeting these genetic changes, 
but efforts are currently underway to identify targets that may 
be specifically lethal in this subset of lung cancers.
Smoking-Related Cancers and  
Genetic Changes
Squamous cell cancers are typically found in smokers, 
and it is possible that the squamous cell carcinomas of the 
aerodigestive system (e.g., lung, esophagus, and head and 
neck) share common genetic alterations. For example, SoX2 
amplification has been reported in both squamous cell carci-
nomas of the lung and the esophagus, and NRF2 mutations 
have been found in squamous cell cancers of the esophagus 
and head and neck. As more is learned about the specific 
genetic changes in different tumor subtypes, we may indeed 
find common themes that link the squamous cell cancers of 
different primary tumor types.
This seems highly likely, given the common risk 
factor of tobacco smoke underlying these cancers. Multiple 
carcinogens have been found in cigarette smoke, including 
PAHs, aza-arenes, N-nitrosamines, aromatic amines, hetero-
cyclic aromatic amines, and aldehydes.118 At least 50 car-
cinogens in cigarette smoke have been identified that cause 
lung tumors in animals or humans.119 Metabolic activation of 
these carcinogens leads to DNA adduct formation, whereby 
the active metabolite binds covalently to DNA. These DNA 
adducts distort the DNA helix and lead to aberrant coding, 
and ultimately the accumulation of mutations leads to loss 
of normal controls on cell growth.120 In addition to the over-
all increase in mutational frequency caused by carcinogens 
from tobacco smoke, there are specific hotspots of mutations 
seen. For example, a dose response relationship between 
tobacco smoke and p53 mutations has been shown, and G to 
T transversions in p53 are more common among smokers 
than among nonsmokers.80,81 Interestingly, newer technologies 
suggest that such changes may be more global than previously 
recognized. Pleasance et al.121 performed deep sequencing 
of a small-cell lung cancer cell line to explore the mutational 
burden associated with smoking. The number of  somatic 
substitutions that were identified was 22,910, of which 134 
(0.6%) were in coding exons. G->T or C->A transversions 
were the most common change, a pattern very similar to what 
is observed in p53. one important challenge will be the sheer 
volume of mutations found in the cancers of heavy smok-
ers. As noted previously, the classical “driver” mutations of 
EGFR and ALK found in lung cancer have been found 
predominantly in never-to-light smokers. It is possible that 
the more complex genetic mutation burden in smokers 
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will make identifying true drivers in this population more 
challenging.
CONCLUSIONS
The treatment of lung cancer has been revolutionized by 
the discovery of specific targeted therapies such as erlotinib 
or gefitinib for EGFR-mutated lung cancer and crizotinib for 
ALK-translocated lung cancer. These successes have taught us 
that lung cancer is not monolithic, but a multitude of different 
diseases best defined by the specific tumor genetic changes 
that are driving tumor growth and that can serve as targets for 
therapy. Although much of the focus to date has been on ade-
nocarcinoma and never-to-light smokers, targets in squamous 
histology and smokers will need to be developed to make a 
broader impact on NSCLC. The current state of knowledge 
of the genomic alterations in squamous cell lung cancer lags 
behind what is known in adenocarcinoma, but as more atten-
tion is focused on this topic, we expect that new targeted ther-
apies for this population will be developed at a rapid pace. 
There are already several potential targetable mutations that 
are being actively pursued in clinical trials, and the upcom-
ing Cancer Genome Atlas analysis in squamous cell should 
also provide a wealth of new information. The Lung Cancer 
Mutation Consortium, a collaboration of clinical genotyping 
efforts in lung adenocarcinomas across a host of different aca-
demic institutions in the United States, provides a model for 
genotyping and genotype-driven clinical trial development. 
Similar focus in squamous cell lung cancer would be invalu-
able in spurring on the development of targeted therapies in 
this area.
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